Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients

Inclusion Criteria: * Patient has been diagnosed with Non-infectious intermediate, posterior and pan-uveitis * Patients voluntarily signed a patient authorization \& informed consent form. * Decision on the treatment with Humira® was made prior to any decision to approach the patient to participate in this study. * Humira® treatment is indicated as per local Summary of Product Characteristics (SmPC) and professional and/or reimbursement guidelines. Exclusion Criteria: * A patient who are contraindications to originator adalimumab (Humira®) as listed on the approved Korean label. * A patient who is participating on other interventional clinical trials * Prior treatment with Humira®, including current course of Humira® started prior to baseline visit assessments.